Biocon Ltd 2025 IR
The report highlights Biocon Group's financial and operational performance for FY25, showcasing a 5% growth in consolidated income to ₹164,699 million. Key achievements include the landmark launch of generic Liraglutide in the UK, marking the company's entry into the GLP-1 market, and the successful USD 800 million bond issuance by Biocon Biologics. On the sustainability front, the group achieved 69% renewable power utilization in India operations and reduced Scope 1 and 2 emissions by 123,609 tCO2e. Additionally, Syngene expanded its global footprint by acquiring its first biologics manufacturing facility in the U.S.
Company: Biocon Ltd
Sector: Health Care
Country: India
Year: 2025
Type: IR
Pages: 421
Biocon Ltd
Integrated Annual Report
The report highlights Biocon Group's financial and operational performance for FY25, showcasing a 5% growth in consolidated income to ₹164,699 million. Key achievements include the landmark launch of generic Liraglutide in the UK, marking the company's entry into the GLP-1 market, and the successful USD 800 million bond issuance by Biocon Biologics. On the sustainability front, the group achieved 69% renewable power utilization in India operations and reduced Scope 1 and 2 emissions by 123,609 tCO2e. Additionally, Syngene expanded its global footprint by acquiring its first biologics manufacturing facility in the U.S.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees